Key facts
- Rgenta Therapeutics’s last known valuation is $119.0M (Nov 2022).
- It has raised $98.9M across 2 recorded rounds; the latest was Early Stage VC ($8.9M) in Nov 2021.
- Notable investors include Korea Investment Partners, CICC Capital, Legend Star, EQT Ventures, Vivo Capital — 13 tracked in total.
- Rgenta Therapeutics has filed 3 Form Ds with the SEC since 2020, most recently Feb 2022 ($8.9M sold to 6 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Rgenta Therapeutics
Funding rounds
2 roundsAbout Rgenta Therapeutics
Developer of a data-driven mRNA target identification platform intended to develop RNA-targeting medicines. The company's platform offers a custom-designed compound library incorporating the physicochemical properties of RNA-binding moieties that account for cell type-specific target regulation and predict the biological consequences of target modulation, enabling medical practitioners to target messenger RNAs of disease genes and open up opportunities for drug development.
- Sector
- Healthcare
- HQ
- Woburn, MA, United States
- Founded
- 2018
- Employees
- 30
- Website
- rgentatx.com/
- Ownership
- Privately Held (backing)
Rgenta Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rgenta Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rgenta Therapeutics in its N-PORT filings yet. We sweep new filings monthly.